Tag: litigation

3D Bio-Printing of Tissues/Organs

“Patent data shows that 55% of the total patent publications in 3d printing of tissue/organ domain are pending patent applications. Higher percentages of applications point to a growing market” Bioprinting refers to an additive manufacturing technique that is used for the creation of organ/tissue-like structures that mimic the natural organs/tissues. 3D printers deposit layers of … Continue reading 3D Bio-Printing of Tissues/Organs

Read more »

Edge Computing: Past And Future

In the past decade, massive growth and increasing computing power of IoT devices has resulted in unprecedented volumes of data. Trends show that there will be a continuous growth of data volumes as 5G networks has increased its number of connected devices. Further there will be the need of efficient management of data. Edge computing … Continue reading Edge Computing: Past And Future

Read more »

Covid-19: Patent, Economy, Prophylaxis and Treatment

Everyone around the globe is suffering from the Covid-19 pandemic and several industries are trying to overcome the economic turmoil.There is a steep decline in product sales & product manufacturing segments, Covid-19 and worldwide lockdowns has severely affected R&D activities as well.However, few industries like the mask, infrared based thermometer, PPE Kits, online meeting tools, … Continue reading Covid-19: Patent, Economy, Prophylaxis and Treatment

Read more »

Recent Developments In Rubber Based Adhesive

Rubber based adhesives are adhesives made using rubber (both natural and synthetic, high molecular weight rubbers and elastomers) as their base material. Rubber based adhesives are generally used as a solvent-based solutions, latex, cements and pressure-sensitive tapes. Rubber based adhesive market was estimated to be USD 56.59 billion in 2018, and is now projected to … Continue reading Recent Developments In Rubber Based Adhesive

Read more »

Patent Trolling

Introduction A patent is an exclusive right that is granted to an inventor for a specified number of years to make, use, and sell an invention. Once the right s provided, no other person can use the invention without proper license from the patentee. This right is provided to protect such inventors legally from any … Continue reading Patent Trolling

Read more »

Enzo Biochem Inc. v. Applera Corp. – A case pertaining to Doctrine of Equivalents

On August 02, 2017, the United States Court of Appealsfor the Federal Circuit ruled in favor of Applera Corp.and Tropix Inc.in the matter of Enzo Biochem Inc., Enzo Life Sciences Inc., Yale University v. Applera Corp., Tropix Inc. The Court affirmed that the district court accurately interpreted proper construction of claims in U.S. Patent No.5,449,767 … Continue reading Enzo Biochem Inc. v. Applera Corp. – A case pertaining to Doctrine of Equivalents

Read more »

Understanding ITC Litigation (Section 337 Cases)

Having seen regular and growing number of queries from Indian Companies on U.S. International Trade Commission (ITC) cases in the US (primarily companies having domestic market in the US), this is a brief attempt to give clarity on jurisdiction that ITC provides, types of cases handled, advantages/disadvantages of the ITC routes, among few other characteristics … Continue reading Understanding ITC Litigation (Section 337 Cases)

Read more »

Let’s Google it !

David Elliot, from Arizona, owned 750 websites with domains like ‘googlegaycruises.com’ and ‘googledonaldtrump.com’ among many others.  His argument was that he needed to use the word ‘google’ because he was developing an internet-based business that will promote charity, commerce, community, relationships, personal health, etc. He further stated that he did not register the domain names … Continue reading Let’s Google it !

Read more »

Actavis and Novartis

ACTAVIS’ “EXPECTATION OF SUCCESS” AFFIRMED ACTAVIS UK vs NOVARTIS AG The High Court, Court of Appeal has recently upheld a decision on Appeal from the High Court, Patents Court, that the Novartis’s European Patent (UK) 0948320, a sustained release formulation of Fluvastatin (a Cholesterol lowering drug), is invalid on the ground of obviousness. Earlier in … Continue reading Actavis and Novartis

Read more »